Meeting
2022 ASCO Annual Meeting
Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data.
Authors
Dawood Findakly
Louisiana State University (Shreveport) Program, Shreveport, LA
Dawood Findakly , Runhua Shi , Gary Von Burton , Samip R. Master
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1051)
DOI
10.1200/JCO.2022.40.16_suppl.1051
Abstract #
1051
Poster Bd #
429
Abstract Disclosures
Similar Posters
First Author: Gabrielle Betty Rocque
Poster
2012 Breast Cancer Symposium
Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.
First Author: Susan Dent
Poster
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
First Author: Ryan Tooker
Poster
2021 ASCO Annual Meeting
Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).
First Author: Fionnuala Crowley